Friday, December 15, 2017 7:04:16 PM
In addition, under Rule 14c-2(b) of the Exchange Act, the Corporate Actions approved on behalf of the Company’s stockholders by the Written Consent may be consummated no earlier than 20 calendar days following the date on which the Definitive Information Statement on Schedule 14C is first mailed to the Company’s stockholders. It is anticipated that the Corporate Actions will be consummated as soon as practicable after the expiration of such 20-day period.
-Dec 14
Recent CRCW News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:00:19 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/30/2023 09:21:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 09:05:38 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 11/30/2023 09:05:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/29/2023 12:21:43 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 12:08:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/17/2023 09:00:35 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 05:40:03 PM
- Blockchain Shares Pop On Form D Filing • AllPennyStocks.com • 10/10/2023 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2023 01:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:00:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 12:00:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 08:00:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM